Perioperative cardiac risks in myasthenia gravis

Area of Science:

• Neurology
• Cardiology
• Immunology

Background:

• Myasthenia gravis (MG) is an autoimmune disorder targeting the neuromuscular junction, primarily through autoantibodies to acetylcholine receptors (AChRs).
• This autoimmune attack reduces functional AChRs, impairing neuromuscular transmission.
• Cardiac involvement is a significant concern in MG, leading to perioperative complications.

Discussion:

• Antistriational antibodies are frequently observed in MG patients with cardiac manifestations.
• The presence of thymoma increases the incidence of cardiac issues in MG patients to 10-15%.
• Cardiac manifestations range from subtle ECG changes to severe conditions like myocarditis, heart failure, and sudden death.

Key Insights:

• MG patients exhibit increased risks of atrial fibrillation, extra systoles, and prolonged QTc intervals.
• Evaluation for autonomic dysfunction is crucial in managing MG patients.
• Clinicians must assess cardiovascular disease risk in individuals with myasthenia gravis.

Outlook:

• Further research into the mechanisms linking MG and cardiac dysfunction is warranted.
• Developing targeted therapies for cardiac complications in MG could improve patient outcomes.
• Enhanced screening protocols for cardiac involvement in MG patients are needed.